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The Authors Reply: We agree with Voss and Hopman that the use of antimicrobial treatment to identify patients with health care-associated infections is a potential limitation, as we acknowledged in the Supplementary Appendix (available with the full text of our article at NEJM.org). On the basis of data from our earlier surveys 1 we believe that this approach was justified in our survey of 183 U.S. hospitals, in which the use of antimicrobial agents was prevalent. However, this approach may not be justified in other countries. In the Dutch national surveys and in a European Centre for Disease Prevention and Control (ECDC) prevalence survey of health careassociated infections and the use of antimicrobial agents in 2011-2012, 2 antimicrobial treatment was more narrowly defined and less prevalent than in our survey. Although 39.9% of the patients in our survey met antimicrobial screening criteria that prompted review for health careassociated infections, just 23.3% of patients in Dutch hospitals in the ECDC survey would have met similar criteria on the basis of antimicrobial agents administered on the survey date. 2 ECDC data also showed that in hospitals outside the Netherlands, 95.5% of health care-associated infections, as compared with 81.3% of these infections in the Netherlands, occurred in patients who were receiving antimicrobial agents. 2 The Centers for Disease Control and Prevention recommends that all U.S. hospitals implement antimicrobial stewardship programs. 3 As prescribing of antimicrobial agents improves, it will be important to reassess the sensitivity of our screening approach. Since publication of their article, the authors report no further potential conflict of interest.
